<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5049">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817657</url>
  </required_header>
  <id_info>
    <org_study_id>CR109001</org_study_id>
    <secondary_id>VAC31518COV4006</secondary_id>
    <nct_id>NCT04817657</nct_id>
  </id_info>
  <brief_title>Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use</brief_title>
  <official_title>COVID Vaccine VAC31518 Pre-approval Access Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this Pre-approval access (PAA) program is to provide VAC31518 (Ad26.CoV2.S)&#xD;
      vaccine for the prevention of coronavirus disease-2019 (COVID-19) infection. This PAA program&#xD;
      may be considered to protect participants against a serious/life-threatening diseases or&#xD;
      conditions, where there are no alternative treatments available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.COV2.S</intervention_name>
    <description>Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1*10^11 virus particles per milliliter (vp/ml) as intramuscular injection.</description>
    <other_name>VAC31518, JNJ-78436735</other_name>
  </intervention>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

